Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Senti Biosciences ( (SNTI) ) just unveiled an update.
On May 14, 2026, Senti Biosciences reported first-quarter 2026 results and highlighted progress on SENTI-202, including positive FDA feedback that supports a single-arm, multi-center pivotal trial design in relapsed/refractory acute myeloid leukemia. The FDA interaction, coupled with Regenerative Medicine Advanced Therapy and Orphan Drug designations, clarified a potential registration path for SENTI-202 and reinforced its positioning as a potential first-in-class off-the-shelf CAR-NK therapy for CD33 and FLT3 expressing hematologic malignancies.
The company also disclosed new clinical insights from its 22-patient Phase 1 trial, noting durable MRD-negative responses and a 50% composite complete response rate in patients treated with Donor X-attribute NK cells, which will now be incorporated into all future SENTI-202 manufacturing. To extend its runway and fund clinical and CMC activities, Senti Bio arranged up to $40 million in senior secured convertible note financing in April 2026 and executed lease and sublease modifications that produced a $6.9 million gain, contributing to a sharply lower net loss of $4.2 million and reduced cash burn of $7.5 million in the quarter despite an $8.9 million cash balance at March 31, 2026.
The most recent analyst rating on (SNTI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Senti Biosciences stock, see the SNTI Stock Forecast page.
Spark’s Take on SNTI Stock
According to Spark, TipRanks’ AI Analyst, SNTI is a Neutral.
The score is held down primarily by very weak financial performance (large ongoing losses, near-zero recent revenue, significant cash burn, and sharply higher leverage from depleted equity). Technical indicators are only neutral and do not offset the longer-term downtrend signal from being far below the 200-day average. Corporate events provide some near-term funding and cost actions, but the terms and structure raise dilution/credit-risk concerns, while valuation is constrained by ongoing losses and no dividend support.
To see Spark’s full report on SNTI stock, click here.
More about Senti Biosciences
Senti Biosciences Holdings, Inc., based in South San Francisco, is a clinical-stage biotechnology company developing next-generation cell and gene therapies using a proprietary synthetic biology Gene Circuit platform. Its wholly owned pipeline focuses on engineered NK and T cell therapies for difficult liquid and solid tumors, with lead program SENTI-202 targeting hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndrome.
The company’s Gene Circuits are designed to precisely kill cancer cells while sparing healthy tissue, increase targeting specificity and enable post-administration control, and have also shown preclinical potential in non-oncology indications. Senti Bio advances additional applications of its technology through partnerships, positioning it within the emerging field of programmable cell and gene therapies.
Average Trading Volume: 159,497
Technical Sentiment Signal: Sell
Current Market Cap: $30.21M
See more data about SNTI stock on TipRanks’ Stock Analysis page.